Key result
Targeted cancer therapies disrupt endogenous cardioprotection, increasing risk of ventricular dysfunction and heart failure.
Why the study?
Many anticancer therapies target signaling pathways essential for myocardial protection against ischemia/reperfusion injury, potentially abrogating stress tolerance and inducing cardiotoxicity or heart failure.
Anti-cancer therapies inherently block signaling cascades required for endogenous myocardial protection, emphasizing the necessity of cardiovascular risk stratification and monitoring in cardio-oncology.
Myocardial protection against ischemia/reperfusion injury (IRI) is mediated by various ligands, activating different cellular signaling cascades. These include classical cytosolic mediators such as cyclic-GMP (c-GMP), various kinases such as Phosphatydilinositol-3- (PI3K), Protein Kinase B (Akt), Mitogen-Activated-Protein- (MAPK) and AMP-activated (AMPK) kinases, transcription factors such as signal transducer and activator of transcription 3 (STAT3) and bioactive molecules such as vascular endothelial growth factor (VEGF). Most of the aforementioned signaling molecules constitute targets of anticancer therapy; as they are also involved in carcinogenesis, most of the current anti-neoplastic drugs lead to concomitant weakening or even complete abrogation of myocardial cell tolerance to ischemic or oxidative stress. Furthermore, many anti-neoplastic drugs may directly induce cardiotoxicity via their pharmacological effects, or indirectly via their cardiovascular side effects. The combination of direct drug cardiotoxicity, indirect cardiovascular side effects and neutralization of the cardioprotective defense mechanisms of the heart by prolonged cancer treatment may induce long-term ventricular dysfunction, or even clinically manifested heart failure. We present a narrative review of three therapeutic interventions, namely VEGF, proteasome and Immune Checkpoint inhibitors, having opposing effects on the same intracellular signal cascades thereby affecting the heart. Moreover, we herein comment on the current guidelines for managing cardiotoxicity in the clinical setting and on the role of cardiovascular confounders in cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Efentakis et al. (2022) conducted a review in Cardiotoxicity from cancer therapies. Anti-neoplastic therapies (VEGF, proteasome, and immune checkpoint inhibitors) was evaluated. Cancer therapies targeting VEGF, the proteasome, and immune checkpoints neutralize endogenous cardioprotective defense mechanisms, leading to an increased risk of ventricular dysfunction and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: